Uric acid Inhibitors
1 drugsAbout Uric acid
Uric acid is a naturally occurring compound in the body involved in metabolic processes. Imbalances in uric acid production or excretion can lead to health issues.
Uric acid has emerged as a therapeutic target for certain metabolic disorders. Currently, there is no genetic evidence data available linking uric acid to specific disease outcomes.
ELITEK (Sanofi) is the only FDA-approved drug targeting uric acid, approved in 2002. It is a biologic (other) modality with 3 indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
Top Uric acid Drugs
Sanofi is the only company with an approved drug targeting uric acid.
The lack of competition suggests a high barrier to entry or an untapped market opportunity.
Uric acid Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Uric acid, using enzyme modality.
Exploring alternative modalities like small molecules could diversify the therapeutic options.
Uric acid Clinical Trials 8 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 4 | 3 | 1 | 0 | 75% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Uric acid Drug Approval Timeline (2002 - 2002)
The first and only drug was approved in 2002.
The long period since the last approval indicates a potential for innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (9 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 10 clinical trials targeting Uric acid.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities